Protalix BioTherapeutics Welcomes Gilad Mamlok as New Senior Vice President and Chief Financial Officer
NEW YORK, NY – July 21, 2025 – Protalix BioTherapeutics, Inc. (NYSE: PLX), a biopharmaceutical company focused on the development and commercialization of protein-based therapeutics, today announced a significant addition to its leadership team. The company is pleased to welcome Gilad Mamlok as its new Senior Vice President and Chief Financial Officer (CFO). This appointment marks a strategic move for Protalix BioTherapeutics as it continues to advance its promising pipeline and strengthen its financial management.
Mr. Mamlok brings a wealth of experience and a proven track record in financial leadership within the biotechnology and pharmaceutical sectors. His expertise is expected to be instrumental in guiding Protalix BioTherapeutics through its next phase of growth, including strategic financial planning, capital allocation, and investor relations.
Prior to joining Protalix BioTherapeutics, Mr. Mamlok held several key financial positions at prominent companies, where he was responsible for a broad range of financial operations. His career has been characterized by a deep understanding of the complexities of the life sciences industry, including navigating the financial intricacies of research and development, clinical trials, and commercial product launches.
The leadership team at Protalix BioTherapeutics expressed enthusiasm for Mr. Mamlok’s arrival. His appointment is seen as a testament to the company’s commitment to attracting top talent and enhancing its operational capabilities. The company believes that Mr. Mamlok’s financial acumen and strategic vision will be invaluable assets as Protalix BioTherapeutics works towards bringing innovative treatments to patients.
This strategic hiring underscores Protalix BioTherapeutics’ dedication to robust financial stewardship and its focus on sustainable growth. The company anticipates that Mr. Mamlok will play a pivotal role in supporting its mission to develop and commercialize important biopharmaceutical products that address significant unmet medical needs.
Protalix BioTherapeutics is currently focused on the advancement of its pipeline, which includes novel protein-based therapies for rare and orphan diseases. The addition of Mr. Mamlok as CFO is expected to further strengthen the company’s ability to achieve its strategic objectives and deliver value to its stakeholders.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer’ at 2025-07-21 10:50. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.